Uncategorized
Share this news article...
Share on LinkedIn
Linkedin
Share on Facebook
Facebook
Tweet about this on Twitter
Twitter
Email this to someone
email

EpiBone, Inc. Receives FDA Clearance to Commence its First-In-Human, Phase 1/2 Trial of its Bone Product, EB-CMF

 

 

 

 

 

EpiBone, Inc. today announced that the U.S. Food and Drug Administration has granted its Investigational New Drug clearance to proceed with a Phase 1/2 clinical trial of its lead bone product EpiBone-Craniomaxillofacial (EB-CMF), as a potential treatment for ramus continuity defects in the mandible. The ramus is a key component of the jaw bone which attaches to the muscles associated with chewing.

 

EB-CMF is a living anatomically correct bone graft manufactured from a patient’s own adipose derived stem cells. This eliminates the need to harvest bone from a patient’s body, potentially reducing pain, surgical and hospitalization time while creating a precision fit with the defect.

 

“We are proud of the work that has been put into this IND, and are grateful to our entire team, as well as all our investors, consultants, and champions in the field who have made this possible,” commented Dr. Nina Tandon, CEO and Co-Founder of EpiBone. “Our technology has the potential to change the field of skeletal reconstruction as we know it. Our goal is to help as many patients as we can to regain optimal form and function, in the most seamless, long-term, and natural way possible.”

 

The Phase 1/2 clinical study will evaluate the EB-CMF product directly in patients with mandibular ramus continuity defects which require reconstruction. In addition to the primary safety of EB-CMF, the study is also designed to demonstrate the effectiveness of EB-CMF in bone reconstruction in addition to integration with the native tissue. The company expects to enroll 6 patients in this study. The company hopes this study will inform the exploration of other potential indications for other facial reconstructive surgeries requiring bone grafts, as well as studies for cartilage replacement in the knee, and other areas of the body.

 

About EpiBone

 

EpiBone, Inc. is privately-held regenerative medicine company focused on skeletal reconstruction. Sitting at the intersection of biology and engineering, the company harnesses the power of a patient’s own cells to create living solutions that become a seamless part of a patient’s body. EpiBone is currently developing a pipeline of bone, cartilage, and compound (bone and cartilage) products.

 

Posted May 23, 2019

Share this news article...
Share on LinkedIn
Linkedin
Share on Facebook
Facebook
Tweet about this on Twitter
Twitter
Email this to someone
email

MORE or "UNCATEGORIZED"


Khiron Announces Closing of $28.75 Million Bought Deal Financing Including Full Exercise of Over-Allotment Option

Khiron Life Sciences Corp. (TSX-V:KHRN) (OTCQB:KHRNF), a cannabis... READ MORE

May 28, 2019

Harborside Closes C$19.65 Million Financing

FLRish Inc. d/b/a/ Harborside, a California corporation which man... READ MORE

May 28, 2019

TerrAscend Announces Closing on $69 Million Non-Brokered Private Placement

TerrAscend Corp. (CSE:TER) (OTCQX:TRSSF) has completed its previo... READ MORE

May 28, 2019

Construction of a hydroelectric generating station for the energy transition in the Inukjuak off-grid system

Innergex Renewable Energy Inc. (TSX: INE) the Pituvik Landholding... READ MORE

May 27, 2019

C21 Investments completes acquisition of Swell Companies

C21 Investments Inc. (CSE: CXXI) (OTC: CXXIF) today announced tha... READ MORE

May 27, 2019

Copyright 2025 The Venture Report